Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-22
2008-01-22
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253010, C544S295000, C544S360000
Reexamination Certificate
active
07320979
ABSTRACT:
The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula Iin whichQ is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Rawhich is/are selected, independently of each other, from halogen, CN, NO2, CO2R4, COR5, C1-C4-alkyl and C1-C4-haloalkyl;Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Rb, which is/are selected from halogen, NO2, CN, CO2R4, COR5, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl and C1-C4-haloalkyl, with it also being possible for two radicals Rbwhich are bonded to adjacent C atoms of Ar to be together C3-C4-alkylene;R1is hydrogen, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C4-alkenyl or C3-C4-alkynyl;with the radicals n, R1, R2, R3, R4and R5having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims1to10and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D3receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function.
REFERENCES:
patent: 4577020 (1986-03-01), Gall
patent: 5958923 (1999-09-01), Hellendahl et al.
patent: 6090807 (2000-07-01), Hellendahl et al.
patent: 6172227 (2001-01-01), Xiang et al.
patent: 6342604 (2002-01-01), Hellendahl et al.
patent: 6380206 (2002-04-01), Pamukcu et al.
patent: 6472392 (2002-10-01), Starck et al.
patent: WO 03/002543 (2003-01-01), None
patent: WO 2004/058265 (2004-07-01), None
Jones et al. Chemical Abstracts, vol. 141, No. 123654 (Abstract for WO 2004/058265, Jul. 15, 2004) (2004).
Database Chemcats, Chemical Abstracts Service, Columbus, Ohio, US; XP002294060.
Willecomme, B.: Recherches dans la série de la pipérizine; Annales de Chimie, vol. 4, No. 6, 1969, pp. 405-428, XP009035691.
Bromidge et al; “5-Chloro-N-(4-methoxy-3-piperazine-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT6 Receptor Antagonist”; Journal of Medicinal Chemistry, American Chemican Society, Washington, D.C. US, vol. 42, No. 2, Jan. 28, 1999, pp. 202-205, XP002109186; ISSN: 0022-2623.
Bromidge, S.M. et al; “Novel (4-piperazin-1-ylquinolin-6-yl) arylsulfonamides with high affinity and selectivity for the 5-HT6 receptor”; Bioorg. med. chem. Lett., vol. 11, 2001, pp. 2843-2846, XP002294076.
J.C. Schwartz, et al., The Dopamine D3Receptor as a Target for Antiphyschotics; Novel Antipsychotic Drugs, Raven Press, Ltd., 1992, pp. 135-144; France.
M. Dooley, et al., Pramipexole—A Review of Its use in the Management of Early and Advanced Parkinson's Disease; Drugs & Aging, 1998, vol. 12, pp. 495-514, New Zealand.
J.N. Joyce, Dopamine D3receptor as a therapeutic target for antiphyschotic and antiparkinsonian drugs; Pharmacology & Therapeutics, 2001, vol. 90, pp. 231-259, USA.
P. Solokoff, et al, Localization and Function of the D3 Dopamine Receptor; Arzneim-Forsch./Drug Res. vol. 42(1), 12992, pp. 224-230, France.
Braje Wilfried M.
Drescher Karla
Geneste Hervé
Grandel Roland
Haupt Andreas
Abbott GmbH & Co. KG.
Bernhardt Emily
Wood Phillips et al.
LandOfFree
N-[(piperazinyl)hetaryl]arylsulfonamide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-[(piperazinyl)hetaryl]arylsulfonamide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-[(piperazinyl)hetaryl]arylsulfonamide compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2799620